Intra-Cellular Therapies Inc. (NASDAQ:ITCI) SVP Kimberly E. Vanover sold 772 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $17.46, for a total value of $13,479.12. Following the sale, the senior vice president now directly owns 12,373 shares of the company’s stock, valued at $216,032.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Intra-Cellular Therapies Inc. (NASDAQ ITCI) traded up $0.47 during trading on Friday, hitting $18.87. The stock had a trading volume of 435,257 shares, compared to its average volume of 489,324. The firm has a market capitalization of $1,030.00, a PE ratio of -8.62 and a beta of 0.72. Intra-Cellular Therapies Inc. has a 1-year low of $7.85 and a 1-year high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.06 million. Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. Intra-Cellular Therapies’s revenue was up 675.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.70) earnings per share. equities analysts forecast that Intra-Cellular Therapies Inc. will post -2.13 EPS for the current year.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research note on Saturday. BidaskClub raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. ValuEngine cut Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Canaccord Genuity initiated coverage on Intra-Cellular Therapies in a research report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price for the company. Finally, SunTrust Banks raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.11.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Franklin Street Advisors Inc. NC boosted its position in Intra-Cellular Therapies by 236.6% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 54,060 shares of the biopharmaceutical company’s stock valued at $783,000 after purchasing an additional 38,000 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in Intra-Cellular Therapies by 80.8% during the third quarter. Public Employees Retirement System of Ohio now owns 69,191 shares of the biopharmaceutical company’s stock valued at $1,092,000 after purchasing an additional 30,915 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Intra-Cellular Therapies during the third quarter valued at $4,114,000. Perceptive Advisors LLC acquired a new stake in Intra-Cellular Therapies during the third quarter valued at $14,667,000. Finally, Premier Asset Management LLC acquired a new stake in Intra-Cellular Therapies during the third quarter valued at $291,000. 74.47% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Intra-Cellular Therapies Inc. (ITCI) SVP Kimberly E. Vanover Sells 772 Shares” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/13/intra-cellular-therapies-inc-itci-svp-kimberly-e-vanover-sells-772-shares.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.